bluuebunny/crossref_metadata_2025_split huggingface dataset:
Two Nucleophilic Mutants of the Micromonospora viridifaciens Sialidase Operate with Retention of Configuration by Two Different Mechanisms
Authors: Watson Jacqueline N. , Newstead Simon , Narine Arun A. , Taylor Garry , Bennet Andrew J. 
Published: October 2005

AbstractMutants of the Micromonospora viridifaciens sialidase, Y370E and Y370F, are catalytically active retaining enzymes that operate by different mechanisms. Previous substitutions with smaller amino acids, including Y370D, yielded inverting sialidases. At least one water molecule can fit into the active‐site cavity of this mutant and act as a nucleophile from the face opposite the leaving group (Biochemistry 2003, 42, 12 682). Thus, addition of a CH2 unit (Asp versus Glu) changes the mechanism from inversion back to retention of configuration. Based on Brønsted βlg values, it is proposed that the Y370E mutant reacts by a double‐displacement mechanism (βlg on kcat/Km −0.36±0.04) with Glu370 acting as the nucleophile. However, the Y370F mutant (βlg on kcat/Km −0.79±0.12) reacts via a dissociative transition state. The crystal structure of the Y370F mutant complexed with 2‐deoxy‐2,3‐dehydro‐N‐acetylneuraminic acid shows no significant active‐site perturbation relative to the wild‐type enzyme.
The Expanding Role of Mass Spectrometry in Metabolite Profiling and Characterization
Authors: Want Elizabeth J. , Cravatt Benjamin F. , Siuzdak Gary 
Published: October 2005

AbstractMass spectrometry has a strong history in drug‐metabolite analysis and has recently emerged as the foremost technology in endogenous metabolite research. The advantages of mass spectrometry include a wide dynamic range, the ability to observe a diverse number of molecular species, and reproducible quantitative analysis. These attributes are important in addressing the issue of metabolite profiling, as the dynamic range easily exceeds nine orders of magnitude in biofluids, and the diversity of species ranges from simple amino acids to lipids to complex carbohydrates. The goals of the application of mass spectrometry range from basic biochemistry to clinical biomarker discovery with challenges in generating a comprehensive profile, data analysis, and structurally characterizing physiologically important metabolites. The precedent for this work has already been set in neonatal screening, as blood samples from millions of neonates are tested routinely by mass spectrometry as a diagnostic tool for inborn errors of metabolism. In this review, we will discuss the background from which contemporary metabolite research emerged, the techniques involved in this exciting area, and the current and future applications of this field.
Venture wire control catheter
Authors: McClure Samuel J. , Wahr Dennis W. , Webb John G. 
Published: October 2005

AbstractWe wished to test the safety and efficacy of a novel wire control catheter for use during percutaneous coronary intervention. The ability to vary the angulation of the tip of an intravascular guidewire would often be desirable. Previous attempts to produce deflectable‐tip guidewire systems have met with limited success. The Venture wire control catheter (Velocimed, Minneapolis, MN) was used to facilitate percutaneous coronary intervention in 20 patients. There were no device‐related complications. Percutaneous coronary intervention was successful in all patients. Our initial experience with the Venture wire control catheter has been favorable. © 2005 Wiley‐Liss, Inc.
Novel Barium Beryllates Ba[Be2N2] and Ba3[Be5O8]: Syntheses, Crystal Structures and Bonding Properties.
Authors: Leoni Stefano , Niewa Rainer , Akselrud Lev , Prots Yurii , Schnelle Walter , Goeksu Tahsin , Cetinkol Mehmet , Somer Mehmet , Kniep Ruediger 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Two Tantalum Fluorides Templated with tren: [H4tren](TaF7)2×H2O and [H4tren](TaF7)2.
Authors: Saada Mohamed Ali , Hemon‐Ribaud Annie , Smiri Laila Samia , Leblanc Marc , Maisonneuve Vincent 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Hydrothermal Synthesis, Crystal Structure, Spectroscopic and Magnetic Properties of (C3H12N2)0.75 [FeII1.5FeIII1.5 (AsO4)F6].
Authors: Bazan B. , Mesa J. L. , Pizarro J. L. , Pena A. , Arriortua M. I. , Rojo T. 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Asymmetric 1,4‐Addition of Potassium Aryltrifluoroborates [ArBF3]K to Enones Catalyzed by Dicationic Palladium(II) Complexes.
Authors: Nishikata Takashi , Yamamoto Yasunori , Miyaura Norio 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Mechanism and Scope of Salen Bifunctional Catalysts in Asymmetric Aldehyde and α‐Ketoester Alkylation.
Authors: Fennie Michael W. , DiMauro Erin F. , O'Brien Erin M. , Annamalai Venkatachalam , Kozlowski Marisa C. 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Ionic Liquid as Catalyst and Reaction Medium. The Dramatic Influence of a Task‐Specific Ionic Liquid, [bmIm]OH, in Michael Addition of Active Methylene Compounds to Conjugated Ketones, Carboxylic Esters, and Nitriles.
Authors: Ranu Brindaban C. , Banerjee Subhash 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
A Rapid and Facile Synthesis of Isoxazolyl and Pyrazolyl Phenols from Enaminoketones Using Montmorillonite under Heterogeneous Catalytic Conditions.
Authors: Reddy G. Jagath , Rao K. Srinivasa , Khalilullah Md. , Latha D. 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Chemo‐ and Stereoselectivity in Titanium‐Mediated Regioselective Ring‐Opening Reaction of Epoxides at the More Substituted Carbon.
Authors: Tanaka Tetsuaki , Hiramatsu Kei , Kobayashi Yasutaka , Ohno Hiroaki 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Selective Oxidation of Benzylic Alcohols and Ethers and Oxidative Cleavage of Benzylic Tetrahydropyranyl and Trimethylsilyl Ethers to Their Carbonyl Compounds by Dinitrogen Tetroxide‐Impregnated Activated Charcoal (N2O4/Carcoal).
Authors: Iranpoor Nasser , Firouzabadi Habibi , Pourali Ali Reza 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Highly Active, Immobilized Ruthenium Catalysts for Oxidation of Alcohols to Aldehydes and Ketones. Preparation and Use in Both Batch and Flow Systems.
Authors: Kobayashi Shu , Miyamura Hiroyuki , Akiyama Ryo , Ishida Tasuku 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Efficient One‐Step Conversion of Tetrahydropyranyl Ethers into Acetates and Formates in the Presence of Potassium Dodecatungstocobaltate K5CoW12O40×3H2O.
Authors: Rafiee E. , Tangestaninejad Sh. , Habibi M. H. , Mohammadpoor‐Baltork I. , Mirkhani V. 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Stereoselective 4‐Benzyloxybut‐2‐enylation of Aldehydes via an Allyl‐Transfer Reaction Using a Chiral Allyl Donor.
Authors: Shafi Siddiqi M. , Chou Jingyu , Kataoka Kazuhide , Nokami Junzo 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Morita—Baylis—Hillman Reaction and Cyclization of 1‐(p‐Toluenesulfonyl)‐1,3‐butadiene with Aldimines.
Authors: Back Thomas G. , Rankic Danica A. , Sorbetti Jovina M. , Wulff Jeremy E. 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Tetraalkylammonium and 1,3‐Dialkylimidazolium Salts with Fluorinated Anions as Recoverable Phase‐Transfer Catalysts in Solid Base Promoted Cross‐Aldol Condensations.
Authors: Kryshtal Galina V. , Zhdankina Galina M. , Zlotin Sergei G. 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Achiral Ligands Dramatically Enhance Rate and Enantioselectivity in the Rh/Phosphoramidite‐Catalyzed Hydrogenation of α,β‐Disubstituted Unsaturated Acids.
Authors: Hoen Rob , Boogers Jeroen A. F. , Bernsmann Heiko , Minnaard Adriaan J. , Meetsma Auke , Tiemersma‐Wegman Theodora D. , de Vries Andre H. M. , de Vries Johannes G. , Feringa Ben L. 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Novel Stereoconvergent Transformation of 1,2a‐Disubstituted 1,2,2a,8b‐Tetrahydro‐3H‐benzo[b]cyclobuta[d]pyran‐3‐ones to 1,3‐Disubstituted 1,2,4a,9b‐Tetrahydrodibenzofuran‐4‐ols and Its Application to the Second‐Generation Synthesis of (.+‐.)‐Linderol A.
Authors: Yamashita Masayuki , Inaba Tomoki , Nagahama Masaki , Shimizu Takashi , Kosaka Sachiko , Kawasaki Ikuo , Ohta Shunsaku 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Improving the Chemistry of N‐Acyliminium Ions: Nucleophilic Substitution Reactions of Pyrrolidinone Derivatives with Trialkylsilyl Nucleophiles Catalyzed by Triisopropylsilyltrifluoromethane Sulfonate (TIPSOTf).
Authors: Othman Raja Ben , Bousquet Till , Fousse Anthony , Othman Mohamed , Dalla Vincent 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Stereoselective Synthesis of N‐Protected Pyrrolidines via Pd‐Catalyzed Reactions of γ‐(N‐Acylamino) Alkenes and γ‐(N‐Boc‐amino) Alkenes with Aryl Bromides.
Authors: Bertrand Myra Beaudoin , Wolfe John P. 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Asymmetric Construction of Quaternary Carbon Stereocenters: High Stereoselection in Mukaiyama Aldol Reactions of 2‐Siloxyindoles with Chiral Aldehydes.
Authors: Adhikari Susanta , Caille Sebastien , Hanbauer Martin , Ngo Vinh X. , Overman Larry E. 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Facile Syntheses of 2,2‐Dimethyl‐6‐(2‐oxoalkyl)‐1,3‐dioxin‐4‐ones and the Corresponding 6‐Substituted 4‐Hydroxy‐2‐pyrones.
Authors: Katritzky Alan R. , Wang Zuoquan , Wang Mingyi , Hall C. Dennis , Suzuki Kazuyuki 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Reactivity of 3‐Styrylchromones as Dienes in Diels—Alder Reactions under Microwave Irradiation: A New Synthesis of Xanthones.
Authors: Pinto Diana C. G. A. , Silva Artur M. S. , Brito Cristela M. , Sandulache Angela , Carrillo Jose R. , Prieto Pilar , Diaz‐Ortiz Angel , de la Hoz Antonio , Cavaleiro Jose A. S. 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Synthesis and Binding Affinity of Novel 3‐Aminoethyl‐1‐tetralones, Potential Atypical Antipsychotics.
Authors: Alvarado Mario , Coelho Alberto , Masaguer Christian F. , Ravina Enrique , Brea Jose , Padin J. Fernando , Loza Maria I. 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
A Facile One‐Step Synthesis of 3‐(2‐Oxo‐2H‐chromen‐3‐yl)‐indeno[2,1‐c]pyridazin‐9‐one.
Authors: Rao V. Rajeswar , Kumar P. Vijaya 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Bismuth Oxide Perchlorate Catalyzed Efficient Synthesis of 3,4‐Dihydropyrimidin‐2(1H)‐ones: An Improved High Yielding Protocol for the Biginelli Reaction.
Authors: Reddy Y. Thirupathi , Reddy P. Narsimha , Kumar B. Sunil , Rao G. V. P. , Rajitha B. 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
N‐Functionalization of Uracil Derivatives: Synthesis of Chiral 2‐(3‐Methyl‐5‐nitro‐2,4‐dioxo‐3,4‐dihydropyrimidin‐1(2H)‐yl)alkanoic Acids and Their Methyl Esters.
Authors: Gondela Andrzej , Walczak Krzysztof 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Synthesis of 6‐(3,5‐Dichlorobenzyl) Derivatives as Isosteric Analogues of the HIV Drug 6‐(3,5‐Dimethylbenzyl)‐1‐(ethoxymethyl)‐5‐isopropyluracil (GCA‐186).
Authors: Soerensen Esben R. , El‐Brollosy Nasser R. , Joergensen Per T. , Pedersen Erik B. , Nielsen Claus 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Synthesis of 3H,9H,10H,10aH‐10‐Aryl‐2‐aryliminothiazolidino[4,5‐b] [1,5]benzodiazepines and Their Alkoxyphthalimide Derivatives.
Authors: Singh Bhawani , Baregama Lalit K. , Ahmed Maqbool , Dixit Neha , Talesara G. L. 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Polyheterocyclic Systems: Synthesis and Biological Activity of Novel Heterocyclic Anellated Compounds from 2,3,4,5‐Tetrahydro‐1‐benzazepin‐5‐one.
Authors: Venkateswarlu Peesapati , Sunkaraneni Suresh Babu 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Syntheses and Spectral Characterization of 2‐Aryloxy‐5,5′‐bis(bromomethyl)‐1,3,2‐dioxaphosphorinane 2‐Oxides.
Authors: Babu M. F. Stephen , Anasuyamma U. , Venugopal M. , Raju C. Naga , Reddy C. Suresh 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Stereoselective Synthesis of (E)‐1‐Iodo‐1‐selenoalkenes via Hydroalumination—Iodination of 1‐Alkynyl Selenides.
Authors: Perez‐Balado Carlos , Lucaccioni Fabio , Marko Istvan E. 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Different Reaction Routes Found in Acid‐Catalyzed Glycosylation of endo‐ and exo‐Glycals: Competition Between Ferrier Rearrangement and Protonation.
Authors: Lin Hui‐Chang , Du Wen‐Ping , Chang Chih‐Chun , Lin Chun‐Hung 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Synthesis, Structure, and Acidic Properties of MCM‐41 Functionalized with Phosphate and Titanium Phosphate Groups
Authors: Kovalchuk T. V. , Sfihi H. , Korchev A. S. , Kovalenko A. S. , Il'in V. G. , Zaitsev V. N. , Fraissard J. 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Self‐Assembled Highly Faceted Wurtzite‐Type ZnS Single‐Crystalline Nanotubes with Hexagonal Cross‐Sections.
Authors: Yin Long‐Wei , Bando Yoshio , Zhan Jin‐Hua , Li Mu‐Sen , Golberg Dmitri 
Published: October 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Epidemiology of cancer‐related fatigue in the Swedish twin registry
Authors: Forlenza Michael J. , Hall Per , Lichtenstein Paul , Evengard Birgitta , Sullivan Patrick F. 
Published: October 2005

AbstractBACKGROUNDEstimates of the prevalence of cancer‐related fatigue (CRF) are wide, and data suggest that fatigue is more prevalent among cancer patients than among the general population. However, most studies examining the prevalence of CRF have been hospital‐based or clinic‐based studies, which often are subject to bias.METHODSPoint prevalence and prevalence odds ratios of fatigue were estimated using data from a large, population‐based cohort that was screened for fatigue and linked with national registry‐based data about cancer. Prevalence odds ratios and 95% confidence intervals were calculated using logistic regression with general estimating equations.RESULTSApproximately 23% of cancer registrants reported abnormal fatigue in the previous 6 months, 19% reported abnormal fatigue that lasted for at least 1 month, 14% reported abnormal fatigue that lasted at least 6 months, and 11% reported abnormal fatigue that lasted at least 6 months and caused significant functional impairment. Individuals who were listed in the cancer registry within the last 5 years were more likely to report experiencing fatigue than individuals who were not listed. There was an elevated prevalence of fatigue among those who were registered with carcinomas of the lung, uterine cervix, colon‐rectum, ovaries, and prostate. Both women and men who were listed recently in the cancer registry were more likely to experience any level of fatigue than the comparison group. However, a greater proportion of women experienced fatigue relative to men.CONCLUSIONSA greater proportion of individuals who were listed in a national cancer registry reported experiencing fatigue compared with individuals in the general population. Cancer 2005. © 2005 American Cancer Society.
Treatment of osteosarcoma at first recurrence after contemporary therapy
Authors: Chou Alexander J. , Merola Pamela R. , Wexler Leonard H. , Gorlick Richard G. , Vyas Yatin M. , Healey John H. , LaQuaglia Michael P. , Huvos Andrew G. , Meyers Paul A. 
Published: October 2005

AbstractBACKGROUNDOverall survival after recurrence of osteosarcoma (OS) is < 30%. The authors reported their experience treating recurrent OS at the time of first recurrence (R1).METHODSPatients with high‐grade OS who achieved complete disease remission (CR) after primary surgery and chemotherapy, and patients who were treated at R1 at Memorial Sloan‐Kettering Cancer Center (New York, NY) after 1990 were analyzed by retrospective chart review.RESULTSFor 43 eligible patients, the median time to R1 from initial diagnosis was 21.7 months (range, 4.6–135.7 mos). The lungs were the most common sites of disease recurrence (n = 33 of 43). With a median follow‐up of 15.2 months (range, 0.7–158.3 mos) after R1, 15 of 43 (35%) patients were alive. Four of 43 patients were treated with surgery alone (3 patients were alive and 1 had died of progressive disease at the time of last follow‐up). Due to unresectable disease, eight patients received only chemotherapy, none of whom survived. For patients with disease recurrence treated with chemotherapy and surgery (n = 31), 22 patients achieved a second CR (CR2). Nine patients were alive and in disease remission (29%) at the time of last follow‐up. Twenty‐three patients received ifosfamide as part of their retrieval regimen. Of the 18 who achieved a CR2, 8 experienced disease recurrence, 7 remain alive in CR2, and 3 died due to toxicity. Eight patients did not receive ifosfamide. Of these, 4 achieved a CR2 but 3 subsequently experienced disease recurrence.CONCLUSIONSAt R1, 22 of 31 patients achieved a CR2 with aggressive surgery and chemotherapy. The majority of these patients subsequently developed a disease recurrence. Patients appeared to benefit from the addition of ifosfamide to their retrieval regimens. In the end, the role of chemotherapy in recurrent OS continues to remain undefined. Cancer 2005. © 2005 American Cancer Society.
Developing a cancer‐specific geriatric assessment
Authors: Hurria Arti , Gupta Supriya , Zauderer Marjorie , Zuckerman Enid L. , Cohen Harvey J. , Muss Hyman , Rodin Miriam , Panageas Katherine S. , Holland Jimmie C. , Saltz Leonard , Kris Mark G. , Noy Ariela , Gomez Jorge , Jakubowski Ann , Hudis Clifford , Kornblith Alice B. 
Published: October 2005

AbstractBACKGROUNDAs the U.S. population ages, there is an emerging need to characterize the “functional age” of older patients with cancer to tailor treatment decisions and stratify outcomes based on factors other than chronologic age. The goals of the current study were to develop a brief, but comprehensive, primarily self‐administered cancer‐specific geriatric assessment measure and to determine its feasibility as measured by 1) the percentage of patients able to complete the measure on their own, 2) the length of time to complete, and 3) patient satisfaction with the measure.METHODSThe geriatric and oncology literature was reviewed to choose validated measures of geriatric assessment across the following domains: functional status, comorbidity, cognition, psychological status, social functioning and support, and nutritional status. Criteria applied to geriatric assessment measurements included reliability, validity, brevity, and ability to self‐administer. The measure was administered to patients with breast carcinoma, lung carcinoma, colorectal carcinoma, or lymphoma who were fluent in English and receiving chemotherapy at Memorial Sloan‐Kettering Cancer Center (New York, NY) or the University of Chicago (Chicago, IL).RESULTSThe instrument was completed by 43 patients (mean age, 74 yrs; range, 65–87 yrs). The majority had AJCC Stage IV disease (68%). The mean time to completion of the assessment was 27 minutes (range, 8–45 mins). Most patients were able to complete the self‐administered portion of the assessment without assistance (78%) and were satisfied with the questionnaire length (90%). There was no association noted between age (P = 0.56) or educational level (P = 0.99) and the ability to complete the assessment without assistance.CONCLUSIONSIn this cohort, this brief but comprehensive geriatric assessment could be completed by the majority of patients without assistance. Prospective trials of its generalizability, reliability, and validity are justified. Cancer 2005. © 2005 American Cancer Society.
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
Authors: Berenson James R. , Jagannath Sundar , Barlogie Bart , Siegel David T. , Alexanian Raymond , Richardson Paul G. , Irwin David , Alsina Melissa , Rajkumar S. Vincent , Srkalovic Gordon , Singhal Seema , Limentani Steven , Niesvizky Ruben , Esseltine Dixie L. , Trehu Elizabeth , Schenkein David P. , Anderson Kenneth 
Published: October 2005

AbstractBACKGROUNDBortezomib, a first‐in‐class proteasome inhibitor, is active with manageable toxicities in relapsed and/or refractory myeloma.METHODSBortezomib 1.0 or 1.3 mg/m2 was administered Days 1, 4, 8, and 11 every 21 days for up to 8 cycles to patients with relapsed and/or refractory myeloma participating in two Phase II trials. Dexamethasone could be added because of progressive disease after 2 cycles or stable disease after 4 cycles. Continuation of or retreatment with bortezomib was offered to patients who, in the investigator's opinion, would benefit from extended treatment.RESULTSSixty‐three patients with relapsed/refractory myeloma treated in this extension trial received a median of 7 additional cycles of therapy, for a total of 14 cycles (range, 7–32) over a median duration of therapy of 45.1 weeks in the parent and extension studies. Seventy‐eight percent of patients completed this study at the same or higher bortezomib dose than they started on during this study, and the treatment schedule of twice‐weekly administration remained unchanged in 89%. Overall, 75% of patients received dexamethasone in combination with bortezomib for a median of 5 cycles starting either in the parent or extension study. The safety profile was similar between the extension and parent trials, with no evidence of new cumulative toxicity. The most commonly reported Grade 3/4 toxicities were thrombocytopenia (29%), with a consistent pattern of recovery during the rest period of each cycle, diarrhea (11%), anemia (11%), and neutropenia (10%). Neuropathy was reported less frequently.CONCLUSIONSRetreatment with or continuation of bortezomib ± dexamethasone beyond 6 months was safe, and toxicities were manageable, in patients with relapsed and/or refractory myeloma. Cancer 2005. © 2005 American Cancer Society.